findmyKOL
Clinical trialNCT01278745TerminatedPhase 2Interventional

Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment362Cardiac Allograft VasculopathyHeart Transplant Recipients
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

All people who have a heart transplant are at risk for developing cardiac allograft vasculopathy (CAV). CAV means narrowing of the heart transplant vessels, which is associated with poor heart transplant function. People who develop antibodies after transplant have a higher risk of developing CAV. Infections, high cholesterol, and rejection also increase the risk of developing CAV. People who develop CAV usually have to receive another transplant.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

24 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Cedars Sinai Heart Institute

    Beverly Hills, California, United States

  • Ronald Regan Ucla Medical Center

    Los Angeles, California, United States

  • Stanford University/palo Alto Va

    Palo Alto, California, United States

  • University of California San Francisco

    San Francisco, California, United States

  • Stanford University

    Stanford, California, United States

  • Northwestern University

    Chicago, Illinois, United States

  • University of Maryland

    Baltimore, Maryland, United States

  • Brigham and Women'S Hospital

    Boston, Massachusetts, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, United States

  • Tufts Medical Center

    Boston, Massachusetts, United States

  • Minneapolis Heart Institute

    Minneapolis, Minnesota, United States

  • University of Minnesota

    Minneapolis, Minnesota, United States

  • Columbia University Medical Center

    New York, New York, United States

  • Mount Sinai School of Medicine

    New York, New York, United States

  • Cleveland Clinic Foundation

    Cleveland, Ohio, United States

  • Drexel University College of Medicine

    Philadelphia, Pennsylvania, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, United States

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania, United States

  • Medical University of South Carolina

    Charleston, South Carolina, United States

  • Medical City Dallas Hospital/crsti

    Dallas, Texas, United States

  • the Methodist Hospital

    Houston, Texas, United States

  • Intermountain Medical Center

    Murray, Utah, United States

  • University of Utah

    Salt Lake City, Utah, United States

  • University of Wisconsin

    Madison, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Rituximab induction/conventional immunosuppressionRituximab placebo/conventional immunosuppression
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Sept 2011
Primary completion
31 Oct 2015
Completion
31 Oct 2015
Last update posted
25 Aug 2020
Registered enrollment
362
Registry id
NCT01278745
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.